Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes Candidates for Ipilimumab
Jedd D. Wolchok, MD, PhD From Memorial Sloan-Kettering Cancer Center describes candidates for ipilimumab.
Dr. Wolchok says many melanoma patients are candidates for ipilimumab, if they have unresectable stage III or stage IV disease. Patients with melanoma that has spread to a distant organ or that has spread to local lymph nodes but can't be surgically removed are patients who, by the current US label, are eligible. The patients who doctors should be careful in using this drug with have a history of autoimmune disease.